| Literature DB >> 26253199 |
Danielle Marie Wenner1, Jonathan Kimmelman2, Alex John London3.
Abstract
Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.Entities:
Mesh：
Year: 2015 PMID： 26253199 DOI： 10.1016/j.stem.2015.07.016
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633